Loading...
Market
Which region will see the highest sales of Nemluvio® in the US by August 13, 2025?
2
Resolution / Starting Odds
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Sales data from Galderma or market research reports
Story
Galderma Gains FDA Approval for Nemluvio® to Treat Prurigo Nodularis
Aug 13, 2024, 05:09 AM
Galderma, a Swiss pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Nemluvio® (nemolizumab). This medication is intended for adult patients suffering from Prurigo Nodularis, a chronic skin condition characterized by itchy nodules. The FDA approval marks a significant advancement for Galderma in the U.S. market, providing a new treatment option for patients with this challenging dermatological condition.
View original story
Similar markets
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%